A new study has identified a potentially serious drawback to a treatment approach for fatty liver disease: blocking an enzyme called Caspase-2 may reduce the condition in the short term but could trigger cancer development over time.
Researchers discovered that when Caspase-2 is inhibited, liver cells begin to enlarge abnormally and accumulate DNA damage. This cellular disruption then progresses to inflammation and scarring, ultimately raising the risk of tumor formation as patients age.
The enzyme had been considered protective, making Caspase-2 inhibition an attractive therapeutic target for treating fatty liver disease. However, the study suggests this approach carries hidden costs that emerge gradually.
The findings highlight a recurring challenge in drug development: interventions that solve an immediate problem can create unforeseen complications when examined over longer periods. While short-term improvements in fatty liver disease may appear promising, the accumulated genetic damage in liver cells appears to set the stage for malignancy.
Fatty liver disease affects millions globally and has become increasingly common alongside obesity and metabolic syndrome. Researchers have been searching for effective pharmaceutical interventions, making enzyme inhibition strategies appealing candidates. This study, however, suggests that blocking Caspase-2 specifically may come with substantial long-term costs.
The research underscores the importance of extended clinical evaluation before new treatments reach widespread use. Rather than simply measuring short-term disease markers, scientists must track whether interventions alter cancer risk or create other delayed complications. For patients with fatty liver disease, the findings suggest that alternative treatment approaches may need exploration before Caspase-2 inhibitors become standard therapy.
Comments